Polyrizon Completes Enrollment of All 120 Patients in NASARIX U.S. Study

summarizeSummary

Polyrizon finished enrolling and randomizing all 120 planned patients across five U.S. sites in its NASARIX allergy blocker study, clearing the way for the clinical data readout. No readout date or results were disclosed.

check_boxKey Events · Product Development and Regulatory · PLRZ

• Enrollment Target Reached

  All 120 planned participants were randomized across five U.S. clinical sites, with 144 individuals screened to reach the target.

• Readout Is Next Binary Event

  The randomized, controlled study compares NASARIX with a saline control in adults with allergic rhinitis; the company expects to proceed with data review and analysis after treatment and follow-up, but gave no readout date.

• Funded by September Raise

  The remaining study activities follow the $4.0 million registered direct offering and concurrent private placement closed in September 2026.

• Prior Site Milestone

  Follows the August 2026 completion of contracts with all five U.S. clinical sites, which set up this enrollment finish.

auto_awesomeAnalysis · PLRZ · Industrial Applications And Services

Full enrollment and randomization is the last operational gate before the clinical data readout, so the NASARIX program now shifts from recruitment risk to execution and data risk. Screening 144 people to fill 120 slots across five U.S. sites implies a modest screen-failure rate, suggesting the trial ran close to plan. The readout itself is what matters next: the study pits NASARIX against a saline control in adults with allergic rhinitis, and a positive result would be the first clinical validation of the Capture and Contain hydrogel barrier. No data, timing or regulatory submission date is given, so the readout remains the single binary event for the equity. Against that backdrop, the September 2026 $4.0 million raise funds the remaining study activities but leaves little room for a miss.